Prevalentie en karakteristieken

Size: px
Start display at page:

Download "Prevalentie en karakteristieken"

Transcription

1 ESBLAT Symposium 2018 Prevalentie en karakteristieken Veilig voedsel produceren ESBLs humaan Marc Bonten

2 Contents 1. Prevalence of carriage with ESBL-producing bacteria. 2. Risk factors for carriage. 3. Transmission of ESBL-producing bacteria. 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5. Consequences of infections with ESBL-producing bacteria.

3 Prevalence of ESBL carriage in healthcare settings % among 337 inhabitants from 8 Long-Term Care Facilities (LTCF) 4.2% E. coli, 5,2% K. pneumoniae (all in 1 LTCF) Courtesy Linda Verhoef, RIVM, SNIV study % among 643 inhabitants of 9 LTCF Willemsen et al. Antimicrob Resist Infect Control. 2014;3: % among 1,351 patients at hospital admission 8.6% when admitted from LTCF 7.9% when admitted from home Platteel et al. Clin Microbiol Infect. 2015; 21: % among 1,871 ICU patients receiving SOD 4.4% among 1,928 ICU patients receiving SDD Oostdijk et al. JAMA, Oct 2014

4 Prevalence of ESBL carriage in Dutch population % (95%CI %) daycare children and parents (van der Bunt et al, J Antimicrob Chemother. 2016;10:XXX) % (95% CI ) ESBL/AmpC prevalence among children attending daycare centers; (Koningstein M, et al. J Pediatric Infect Dis Soc. 2015;4(4):e93 9) % (95% CI ) ESBL/AmpC prevalence among adults in living in livestockdense area; (Wielders C., et al. Clin Microbiol Infect. 2017;23:120e1 8) % (95% CI ) overall ESBL/AmpC prevalence in a general population (high and low broiler density area); (Huijbers PMC, et al. Clin Microbiol Infect. 2013;19(6):E256 9) % (95% CI ) ESBL carriage elderly at hospital admission (Platteel TN, et al. Clin Microbiol Infect. 2015;21: ) % (95% CI ) ESBL carriage before travelling (Paltansing S, et al. Emerg Infect Dis. 2013) % (95% CI ) ESBL carriage among citizens of Amsterdam (Reuland EA, et al. J Antimicrob Chemother. 2016;10:1-7) % (95% CI ) patients visiting GP with gastrointestinal complaints (Reuland EA, et al. Clin Microbiol Infect. 2013;19(6):542 9)

5 Prevalence of ESBL carriage in Dutch population % (95%CI %) daycare children and parents (van der Bunt et al, J Antimicrob Chemother. 2016;10:XXX) % (95% CI ) ESBL/AmpC prevalence among children attending daycare centers; (Koningstein M, et al. J Pediatric Infect Dis Soc. 2015;4(4):e93 9) % (95% CI ) ESBL/AmpC prevalence among adults in living in livestockdense area; (Wielders C., et al. Clin Microbiol Infect. 2017;23:120e1 8) % (95% CI ) overall ESBL/AmpC prevalence in a general population (high and low broiler density area); (Huijbers PMC, et al. Clin Microbiol Infect. 2013;19(6):E256 9) % (95% CI ) ESBL carriage elderly at hospital admission (Platteel TN, et al. Clin Microbiol Infect. 2015;21: ) % (95% CI ) ESBL carriage before travelling (Paltansing S, et al. Emerg Infect Dis. 2013) % (95% CI ) ESBL carriage among citizens of Amsterdam (Reuland EA, et al. J Antimicrob Chemother. 2016;10:1-7) % (95% CI ) patients visiting GP with gastrointestinal complaints (Reuland EA, et al. Clin Microbiol Infect. 2013;19(6):542 9)

6 ESBLAT Study design ESBLs in humans (Monthly repeated crosssectional) Prevalence and genotypes in the Dutch human population Risk factors for ESBL carriage in humans ESBLs in pets (Monthly repeated crosssectional) Pets Prevalence and genotypes of ESBLs in Dutch dogs and cats Risk factors for ESBL carriage in dogs and cats Persistence of ESBLs in humans and pets (follow-up after 1 and 6 months after first sample) UMCU/RIVM UU Faculty of Veterinary Medicine

7 ESBLAT Study design: inclusion Dutch general population Humans Invited: n= Participation y/n? Y N Willing to participate in Human Faecal sampling? Faecal sample Y N Questionnaire & faecal sample N= (8,7%) Only questionnaire N= (9,6%) No information N=39.169

8 Representativeness of ESBLAT study population Source: CBS 2017 Netherlands 2015 N=16,900,726 ESBLAT N=4,177 Difference <20 years 22.7% 14.5% -8,2% 20 to 39 years 24.5% 12.5% -12,0% 40 to 64 years 35.1% 45.0% +10,1% 65 to 79 years 13.4% 24.7% +11,3% >80 years 4.3% 3.2% -1,1% Average age population ,5yr Parents both born in the Netherlands 78.3% 97.5% +19,2% Gender (Male) 49.5% 45.5% +4% Degree of urbanization (adresses per km2) >= % 5.4% -17,3% % 15.0% -9,8% % 19.5% +2,2% % 27.9% +10,3% < % 32.2% +14,6% County Groningen / Friesland / Drenthe 10,2% 12,4% +2,2% Overijssel / Flevoland / Gelderland 21,1% 24,3% +3,3% Utrecht / N-Holland / Z-Holland 45,1% 37,5% -7,6% Zeeland / N-Brabant / Limburg 23,6% 25.,6% -2%

9 Participants aggregated per municipality

10 ESBLAT Results Prevalence of ESBL carriage: 186/ % (95%CI: %) E. coli: 178 (93.7%) K. pneumonia: 10 (5.2%) E. cloacae complex: 2 (1.1%) Adjusted for: Prevalence (%) 95% CI Gender Age County Degree of urbanisation Nationality E. coli genotypes: blactx-m15: 85 (44.5%) blactx-m1: 30 (15.7%) blactx-m14: 31 (16.2%) blactx-m27: 27 (14.1%) E. coli sequence types: ST131: 42 (23.6%) ST38: 22 (12.4%) ST10: 14 (7.9%)

11 ESBL positieve participants

12 Contents 1. Prevalence of carriage with ESBL-producing bacteria. 2. Risk factors for carriage. 3. Transmission of ESBL-producing bacteria. 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5. Consequences of infections with ESBL-producing bacteria.

13 Univariately tested variables (of 86 variables) General characteristics: - Gender - Country of birth is other than the Netherlands - Age - Social Economic Status (SES) - Degree of urbanization - Season of sampling - Year of sampling - Level of education Health care related: - Admission to hospital in 4 weeks prior to sample collection - Hospitalization in the past 12 months - Used antibiotics in 8 weeks prior to sample collection - Used antibiotics in the past (never, <6 months, 6-12 months, >12 months) - Used of proton pump inhibitors in the past 6 months Exposure related: - Attending day care of at least 1 child in household - Ate raw or undercoocked meat 1 week in the past week - Eat no meat - Eat pork - Eat in a restaurant more often than 20 times a year - Being abroad: - in the 4 weeks prior to sample collection - in the past 12 months - Animals in or around the household - Not changing the kitchen towel on a daily basis - Swam: - in sea or ocean ('salt' water) in the past 4 weeks - in sea or ocean ('salt' water) in the past 12 months - in open fresh water (lakes, river, etc.) in the past 4 weeks - in open fresh water (lakes, river, etc.) in the past 12 months

14 ESBLAT: Risk factors identified univariate multivariate* Variable OR 95% CI OR 95% CI Gender (Male) 1,25 0,93 1,68 1,44 1,01 2,05 Country of birth is other than the Netherlands 2,32 1,28 4,19 2,34 1,18 4,61 Eat in a restaurant more often than 20 times a year 1,96 1,33 2,90 1,74 1,09 2,78 used antibiotics in the past never <6 months 2,43 1,28 4,60 2,06 1,02 4, months 1,66 0,96 2,87 1,64 0,73 3,68 >12 months 1,64 0,77 3,48 1,43 0,79 2,59 Ate pork 0,61 0,37 1,02 Swam in sea or ocean ('salt' water) in the past 12 months 1,56 1,14 2,13 1,46 1,0 2,14 Not changing the kitchen towel on a daily basis 2,20 1,41 3,43 2,15 1,27 3,62 Travelled (in the past 12 months): Not travelled to Europe 1,19 0,83 1,69 0,83 0,54 1,29 to Africa 3,85 1,73 8,5 3,03 1,23 7,46 to Asia 3,73 2,18 6,35 2,00 1,02 3,90 to North-America 1,34 0,52 3,46 0,17 0,02 3,62 *controlled for the following variables: age (0-4, 5-12, 12-19, 20-39, 40-64, 95-79, >80) and season (autumn(september November), winter (December February), spring (March May), summer (June August)).

15 633 (34 3%) of 1847 travellers had acquired ESBL-E during international travel, especially in southern Asia (75 1%). Median duration of colonisation after travel was 30 days. 65 (11 3%) of 577 remained colonised at 12 months.

16

17 Prevalence ESBLAT: Traveling to Africa and Asia in the past 12 months 35,00 30,00 25,00 20,00 15,00 10,00 5,00 0,00 ESBL prevalence in participants travelled in the past year % ESBL Continent ESBL N % ESBL Africa ,31 Asia ,00 Europe ,15 North- America ,67 Oceania South- America ,55 Continent

18 ESBLAT: other risk factors Eat more than 20 times a year in a restaurant Associated with travel, higher SES Swam in sea or ocean ('salt' water) in the past 12 months Associated with travelling Not changing the kitchen towel on a daily basis Associated with Not changing the dish towel on a daily basis, Not always cleaning hands before preparing food, Not always cleaning hands after toilet visit

19 Percentage ESBLAT: PPI not a risk factor Reuland EA, et al. J Antimicrob Chemother. 2016;10: ESBLAT: Proton Pump Inhibitor Use per age category >80 Age category and 5,3% in PPI (32/599) % PPI use Subgroup analysis in 40+ group: ESBL + 4,4% (105/2395) in non-ppi

20 Contents 1. Prevalence of carriage with ESBL-producing bacteria. 2. Risk factors for carriage. 3. Transmission of ESBL-producing bacteria. 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5. Consequences of infections with ESBL-producing bacteria.

21 R 0 R 0 is the average number of new cases of an infection caused by one infected individual in a population of susceptibles R 0 > 1 : each infected spreads the infection to more than one other person/animal: chain reaction = epidemic R 0 < 1 : on average an infected does not replace itself in the infected population: infection cannot grow

22 633 (34 3%) of 1847 travellers had acquired ESBL-E during international travel, especially in southern Asia (75 1%). Median duration of colonisation after travel was 30 days. 65 (11 3%) of 577 remained colonised at 12 months. Onward transmission was found in 13 (7 7%) of 168 household members. The probability of transmitting ESBL-E to another household member was 12%. Calculated effective R0 was around 0.2 (Martin Bootsma personal communication), which might include some overestimation due to false-positive transmission events (no molecular typing).

23 Acquisition of ESBL carriage in Dutch hospitals Rectal carriage of ESBL-E Prevalence at admission % [95% CI/CrI] Prevalence at discharge % [95% CI /CrI] Hospital-acquired prevalence at discharge % [95%CI/Crl] Acquisition rate n/1000 patientdays at risk [95% CI/CrI) SoM study 14 hospitals 8,400 admissions 7.4% [6.2%-8.7%] 9.9% [8.2%-11.8%] 2.5% [1.7%-3.6%] 3.2 [ ] R-GNOSIS study Single hospital 5,450 admissions 6.4% [5.2%-7.8%] 8.7% [6.8%-11.0%] 2.3% [1.3%-3.6%] Results: MCMC model 28.5% cross-transmission 71.5% endogenous selection R= [ ] Mathematical model (data R- GNOSIS study) 7.0% [6.2%-7.8%] 9.3% [8.6%-10.0%] 2.3% [1.7%-2.9%] 3.8 [ ] Kluytmans-van de Bergh, Mens, et al. ICHE 2017

24 Contents 1. Prevalence of carriage with ESBL-producing bacteria. 2. Risk factors for carriage. 3. Transmission of ESBL-producing bacteria. 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5. Consequences of infections with ESBL-producing bacteria.

25 % Resistamt to 3rd gen cephalosporins Trends in prevalence of ESBL-producing bacteria as a cause of bloodstream infections in ISIS-AR Data from 21 labs E. coli: 3,257-4,035/yr K. pneumoniae: /yr E. coli K. pneumoniae

26 Effect of national policy implemented in 2010 Sales data of antimicrobials for use in animals in the Netherlands DDD/AY for different sectors DD/DJ en DDDAnat % reduction ( ) 64.4% reduction in 2016 to reference year 2009 Fluoroquinolones and 3 rd /4 th -gen cefalosporines usage reduced to a minimum 68% reduction in use of colistin ( ) Purple: turkeys Blue: veal Orange: broilers Light green: pigs Dark green: dairy Jaar 26

27 Clinical suspicion of GNB infection (BC + start Abs) N=9,422 GNB bacteremia N=773 (8,2%) GNB: 3GCeph-S N=709 (7,2%) GNB: 3GCeph-R N=64 (0,7%) 3GCeph-R/all GNB N=64/773 (9%) Rottier et al. CID, 2015

28 Contents 1. Prevalence of carriage with ESBL-producing bacteria. 2. Risk factors for carriage. 3. Transmission of ESBL-producing bacteria. 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5. Consequences of infections with ESBL-producing bacteria.

29 Courtesy: W. Rottier The association between antibiotic resistance and outcome M 2 : mortality M 2 G 1 : appropriateness of empiric therapy G 1 R 0 : resistance of bacterial strain R 0

30 U -1 X* -1 M 2 : mortality M 2 E -1 T 1 X* -1 : underlying disease U -1 : measurable X* -1 E -1 : exposure to healthcare A -1 : exposure to antibiotics C* -1 : colonizing bacterial strain K -1 : known colonization with bacterial strains A -1 C* -1 K -1 C* 0 F 0 P 0 V* 0 R 0 D 1 G 1 C* 0 : bacterial strain causing infection K 0 : known properties of C* 0 F 0 : infection source P 0 : sepsis severity V* 0 : virulence of bacterial strain R 0 : resistance of bacterial strain K 0 D 1 : source control T 1 : empiric antibiotic therapy G 1 : appropriateness of empiric therapy

31 To retrospectively - determine associations between appropriateness of initial antibiotic treatment and other factors associated with day 30 mortality in patients with ESBL bacteremia in 8 Dutch hospitals. 232 consecutive patients (bacteremia due to E. coli, K. pneumoniae and Enterobacter spp) between 2008 and 2010.

32 Variable Variables associated with day-30 mortality Unadjusted OR in univariate analysis Adjusted OR in multivariable analysis Appropriate therapy No (vs Yes) 1.12 ( ) 1.53 ( ) Charlson index >3 (vs <3) 2.16 ( ) 2.80 ( ) Patient age >75 yr (vs <75) 2.35 ( ) 3.81 ( ) Hospital ward at bacteremia onset ICU (vs other) 3.99 ( ) 2.88 ( ) Bacteremia source Non-UTI (vs UTI) 4.31 ( ) 4.79 ( ) Severe sepsis Yes (vs No) 7.24 ( ) 5.24 ( )

33 GRAND-ABC: Burden of Infections Caused by Antibiotic Resistant Gram-Negative Bacteria in the Netherlands Courtesy: Wouter Rottier

34 Conclusions (1) 1. Prevalence of human carriage with ESBL-producing bacteria. 4,5% in open population 8% in LTCF 8% in hospital 4% in ICU 2. Risk factors for carriage in open population. Travelling (esp Asia and Africa) Salt water exposure (linked to travelling) Restaurant exposure (linked to travelling) Antibiotic use Non-hygienic kitchen behavior

35 Conclusions (2) 3. Transmission of ESBL-producing bacteria. Within household: R 0,2 Within hospital: R 0,06 4. Prevalence and incidence of infections with ESBLproducing bacteria. 5% among invasive E. coli infections 8% among invasive K. pneumoniae infections 0.7% when starting empiric antibiotic therapy for sepsis Prevalence stable during last 7 years 5. Consequences of infections with ESBL-producing bacteria. Transmission of ESBL-producing bacteria. No evidence of increased mortality or increased healthcare burden

36 Acknowledgements Department of Medical Microbiology, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands Gerrita van der Bunt A.C. Fluit L. Hidalgo J. Scharringa J. Vlooswijk L.J.L. Muller G.M.A. Riemens-Zetten Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands: W. Van Pelt L. Mughini-Gras A. Mulder Central Veterinary Institute (CVI) of Wageningen University, Lelystad, the Netherlands D.J. Mevius Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands J. Hordijk M.P. Spaninks A.J. Timmerman J.A. Wagenaar Workgroup ESBL Attribution (ESBLAT): Utrecht University-Institute for Risk Assessment Sciences Utrecht University Department of Infectious Diseases & Immunology University Medical Centre Utrecht National Institute for Public Health and the Environment GD-Animal Health VION-FOOD Group van Drie Group

37 Hypothesis: Infections caused by antibiotic resistant bacteria increase the risk of recurrent infetion. Aim: To quantify the association between antibiotic resistance and the occurrence of recurrent bacteremia. Data source: All blood cultire isolates of Enterobacteriaceae in ISIS- AR, covering 60% of all microbiological culture results since 2010 (analysis till Sept 2016).

38 ESBL ESBL+CRE ESBL ESBL+CRE The absolute risk of a recurrent infection caused by ESBL or ESBL/CRE after a first episode caused by a susceptible isolate was 0.1% (74/ episodes). The estimated number of recurrent bacteremia episodes with ESBL or ESBL/CRE in the Netherlands is 19/year.

39 we used genomics to analyze a systematic 11-yr hospitalbased survey of E. coli associated with bacteremia using isolates collected from across England by the British Society for Antimicrobial Chemotherapy and from the Cambridge University Hospitals NHS Foundation Trust.

40 Proportions of STs during the 11-yr sampling framework. Teemu Kallonen et al. Genome Res. 2017;27: Kallonen et al.; Published by Cold Spring Harbor Laboratory Press

41

42 % Resistamt to 3rd gen cephalosporins E. coli K. pneumoniae

43 Prevalence and relative contributions of hospital acquisition, travel acquisition, within-household transmission, and between-household transmission to the prevalence of ESBL. B/W, between-household transmission rate defined as a fraction of the within-household transmission rate.

44

45

LA-MRSA in the Netherlands: the past, presence and future.

LA-MRSA in the Netherlands: the past, presence and future. LA-MRSA in the Netherlands: the past, presence and future. Prof. Jaap Wagenaar DVM, PhD With input from Prof. Jan Kluytmans MD, PhD Department of Infectious Diseases and Immunology, Faculty of Veterinary

More information

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?

Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and

More information

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version

Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control

More information

Lindsay E. Nicolle University of Manitoba Winnipeg, CANADA

Lindsay E. Nicolle University of Manitoba Winnipeg, CANADA Lindsay E. Nicolle University of Manitoba Winnipeg, CANADA Long Term Care Facilities: Spectrum low acuity assisted living mobile independent Not LTAC high acuity complete functional disability dialysis

More information

Bacterial infections complicating cirrhosis

Bacterial infections complicating cirrhosis PHC www.aphc.info Bacterial infections complicating cirrhosis P. Angeli, Dept. of Medicine, Unit of Internal Medicine and Hepatology (), University of Padova (Italy) pangeli@unipd.it Agenda Epidemiology

More information

Antimicrobial Cycling. Donald E Low University of Toronto

Antimicrobial Cycling. Donald E Low University of Toronto Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and

More information

Successful stewardship in hospital settings

Successful stewardship in hospital settings Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com

More information

MDRO in LTCF: Forming Networks to Control the Problem

MDRO in LTCF: Forming Networks to Control the Problem MDRO in LTCF: Forming Networks to Control the Problem Suzanne F. Bradley, M.D. Professor of Internal Medicine Division of Infectious Disease University of Michigan Medical School VA Ann Arbor Healthcare

More information

Hosted by Dr. Jon Otter, Guys & St. Thomas Hospital, King s College, London A Webber Training Teleclass 1

Hosted by Dr. Jon Otter, Guys & St. Thomas Hospital, King s College, London A Webber Training Teleclass   1 Andreas Voss, MD, PhD Professor of Infection Control Radboud University Nijmegen Medical Centre & Canisius-Wilhelmina Hospital Nijmegen, Netherlands Hosted by Dr. Jon O0er Guys & St. Thomas NHS Founda

More information

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.

Active Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply. Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted

More information

MRSA found in British pig meat

MRSA found in British pig meat MRSA found in British pig meat The first evidence that British-produced supermarket pig meat is contaminated by MRSA has been found in new research commissioned by The Alliance to Save Our Antibiotics

More information

Community-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018

Community-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018 Community-Associated C. difficile Infection: Think Outside the Hospital Maria Bye, MPH Epidemiologist Maria.Bye@state.mn.us 651-201-4085 May 1, 2018 Clostridium difficile Clostridium difficile Clostridium

More information

120 mln. 17 mln. The Netherlands. 12 million swine. 100 million poultry. 1,5 million dairy cows. 1 million veal calves. 1,5 million sheep and goats

120 mln. 17 mln. The Netherlands. 12 million swine. 100 million poultry. 1,5 million dairy cows. 1 million veal calves. 1,5 million sheep and goats FMM/RAS/298: Strengthening capacities, policies and national action plans on prudent and responsible use of antimicrobials in fisheries Final Workshop in cooperation with AVA Singapore and INFOFISH 12-14

More information

Infection control: Need for robust guidelines

Infection control: Need for robust guidelines Infection control: Need for robust guidelines Hans Jørn Kolmos MD DMSc Professor, consultant Department of Clinical Microbiology Odense University Hospital hans.joern.kolmos@ouh.regionsyddanmark.dk Combating

More information

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012

Inappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012 Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton

More information

Fighting MDR Pathogens in the ICU

Fighting MDR Pathogens in the ICU Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial

More information

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update

Presenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's

More information

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?

More information

Surveillance of AMR in PHE: a multidisciplinary,

Surveillance of AMR in PHE: a multidisciplinary, Surveillance of AMR in PHE: a multidisciplinary, integrated approach Professor Neil Woodford Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright International

More information

Why should we care about multi-resistant bacteria? Clinical impact and

Why should we care about multi-resistant bacteria? Clinical impact and Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased

More information

Multi-drug resistant microorganisms

Multi-drug resistant microorganisms Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the

More information

Table 2.01 Overview of Surveillance programs in the Netherlands. available since. GP, laboratories Decentral Hospital,

Table 2.01 Overview of Surveillance programs in the Netherlands. available since. GP, laboratories Decentral Hospital, 2 Extensive summary In the Netherlands, several surveillance programs have been developed to monitor antimicrobial resistance in important pathogens in different settings (SERIN, SIRIN, ISIS- AR). In addition,

More information

(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE

(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE (DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE John Ferguson (Hunter New England, NSW) on behalf of MRGN Task Force Acknowledgement

More information

Study Protocol. The effects of SDD and SOD on antibiotic resistance in the ICU: A multi-center comparison.

Study Protocol. The effects of SDD and SOD on antibiotic resistance in the ICU: A multi-center comparison. Study Protocol The effects of SDD and SOD on antibiotic resistance in the ICU: A multi-center comparison. November 2009 Version 10 Working title: SDD and SOD and antibiotic resistance in the ICU Local

More information

Mono- versus Bitherapy for Management of HAP/VAP in the ICU

Mono- versus Bitherapy for Management of HAP/VAP in the ICU Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,

More information

Burden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital

Burden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital Burden of disease of antibiotic resistance The example of MRSA Eva Melander Clinical Microbiology, Lund University Hospital Discovery of antibiotics Enormous medical gains Significantly reduced morbidity

More information

DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA

DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat

More information

Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S

Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S Carbapenemase-producing Enterobacteriaceae (CRE) T H E L A T E S T I N T H E G R O W I N G L I S T O F S U P E R B U G S CRE Enterobacteriaceae (Gram Negative Bacilli) Citrobacter species Escherichia coli***

More information

Gram negative bacteraemia

Gram negative bacteraemia Gram negative bacteraemia David Enoch Consultant Medical Microbiologist PHE Cambridge Cambridge University Hospitals NHS FT Overview Gram negative bacteraemia Changing epidemiology in England Epidemiology

More information

Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland

Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland Thanks for material provided by Marlieke de Kraker & Andrew

More information

10 Golden rules of Antibiotic Stewardship in ICU. Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017

10 Golden rules of Antibiotic Stewardship in ICU. Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017 10 Golden rules of Antibiotic Stewardship in ICU Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017 10 golden rules of Antibiotic Stewardship in the ICU ID, Pharma & Micro advice

More information

Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters

Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Jon Otter, PhD Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas'

More information

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Oostdijk EAN, Kesecioglu J, Schultz MJ, et al. Effects of decontamination of the oropharynx and intestinal tract on antibiotic resistance in ICUs: a randomized clinical trial.

More information

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Antimicrobial resistance I: Situation and strategies in Europe

Antimicrobial resistance I: Situation and strategies in Europe Antimicrobial resistance I: Situation and strategies in Europe Global Past, Present and Future Challenges in Risk Assessment Strengthening Consumer Health Protection Berlin, November 30th December 1st,

More information

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly

Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

Evaluating the Role of MRSA Nasal Swabs

Evaluating the Role of MRSA Nasal Swabs Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization

More information

Reduction of Antibiotics in poultry meat production. Dutch action plan. Ben Dellaert Director Avined Buenos Aires, 27th October 2016

Reduction of Antibiotics in poultry meat production. Dutch action plan. Ben Dellaert Director Avined Buenos Aires, 27th October 2016 Reduction of Antibiotics in poultry meat production Dutch action plan Ben Dellaert Director Avined Buenos Aires, 27th October 2016 Content 1. Results 2. Motives 3. Policy and collaboration 4. Action plan

More information

Original Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):

Original Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4): Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S

More information

Surveillance of Multi-Drug Resistant Organisms

Surveillance of Multi-Drug Resistant Organisms Surveillance of Multi-Drug Resistant Organisms Karen Hoffmann, RN, MS, CIC Associate Director Statewide Program for Infection Control and Epidemiology (SPICE) University of North Carolina School of Medicine

More information

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier

More information

A summary index for antimicrobial resistance in food animals in the Netherlands

A summary index for antimicrobial resistance in food animals in the Netherlands Havelaar et al. BMC Veterinary Research (2017) 13:305 DOI 10.1186/s12917-017-1216-z RESEARCH ARTICLE A summary index for antimicrobial resistance in food animals in the Netherlands Arie H. Havelaar 1,2,3*,

More information

8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM

8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM Mary Moore, MS CIC MT (ASCP) Infection Prevention Coordinator Great River Medical Center, West Burlington REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM ABOUT

More information

Nosocomial Infections: What Are the Unmet Needs

Nosocomial Infections: What Are the Unmet Needs Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com

More information

Traveling (resistant) bacteria

Traveling (resistant) bacteria Traveling resistant bacteria Erika Vlieghe Institute of Tropical Medicine, Antwerp University Hospital Antwerp Traveling (resistant) bacteria Colonisation - carriership rectal flora, skin Infection: mild-moderate

More information

Typhoid fever - priorities for research and development of new treatments

Typhoid fever - priorities for research and development of new treatments Typhoid fever - priorities for research and development of new treatments Isabela Ribeiro, Manica Balasegaram, Christopher Parry October 2017 Enteric infections Enteric infections vary in symptoms and

More information

CDI Management in Post-Acute Care: Part 1

CDI Management in Post-Acute Care: Part 1 CDI Management in Post-Acute Care: Part 1 Robin Jump, MD, PhD VISN10 Geriatric Research Education and Clinical Center (GRECC) Louis Stokes Cleveland VA Medical Center Case Western Reserve University Robin.Jump@va.gov

More information

Is biocide resistance already a clinical problem?

Is biocide resistance already a clinical problem? Is biocide resistance already a clinical problem? Stephan Harbarth, MD MS University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland Important points Biocide resistance exists Antibiotic

More information

EFSA s activities on Antimicrobial resistance in the food chain. Dr. Ernesto Liebana Head of BIOCONTAM Unit. EFSA

EFSA s activities on Antimicrobial resistance in the food chain. Dr. Ernesto Liebana Head of BIOCONTAM Unit. EFSA EFSA s activities on Antimicrobial resistance in the food chain Dr. Ernesto Liebana Head of BIOCONTAM Unit. EFSA EFSA IS The reference body for risk assessment of food and feed in the European Union. Its

More information

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA

More information

Summary of the latest data on antibiotic resistance in the European Union

Summary of the latest data on antibiotic resistance in the European Union Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network

More information

EVOLUTION OF THE ENDOGEN FLORA SUSCEPTIBILITY PROFILES AMONG MEDICAL STUDENTS IN ACCORDANCE WITH THEIR YEAR OF STUDY

EVOLUTION OF THE ENDOGEN FLORA SUSCEPTIBILITY PROFILES AMONG MEDICAL STUDENTS IN ACCORDANCE WITH THEIR YEAR OF STUDY EVOLUTION OF THE ENDOGEN FLORA SUSCEPTIBILITY PROFILES AMONG MEDICAL STUDENTS IN ACCORDANCE WITH THEIR YEAR OF STUDY G E B R A E L S A L I B A, M D, M P H C L I N H D F 2017 U N I V E R S I T É S A I N

More information

Infection Control of Emerging Diseases

Infection Control of Emerging Diseases 2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event

More information

Antimicrobial Resistance

Antimicrobial Resistance Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of Change in the approach to the administration of empiric antimicrobial therapy Increased

More information

MRSA control strategies in Europekeeping up with epidemiology?

MRSA control strategies in Europekeeping up with epidemiology? MRSA 15 years in Belgium MRSA control strategies in Europekeeping up with epidemiology? Marc J. Struelens, MD, PhD Senior Expert, Scientific Advice Unit European Centre for Disease Prevention and Control,

More information

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC

Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant

More information

Antibiotic resistance in West Africa

Antibiotic resistance in West Africa Antibiotic resistance in West Africa Prof. Pierre Tattevin Infectious Diseases and ICU, Pontchaillou University Hospital, Rennes, France International Society of Chemotherapy No conflict of Interest International

More information

Screening programmes for Hospital Acquired Infections

Screening programmes for Hospital Acquired Infections Screening programmes for Hospital Acquired Infections European Diagnostic Manufacturers Association In Vitro Diagnostics Making a real difference in health & life quality June 2007 HAI Facts Every year,

More information

HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE

HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Universidade de São Paulo Departamento de Moléstias Infecciosas e Parasitárias HEALTHCARE-ACQUIRED INFECTIONS AND ANTIMICROBIAL RESISTANCE Anna S. Levin 4 main lines! Epidemiology of HAS and resistance!

More information

Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered

Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length

More information

MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance

MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation

More information

Other Enterobacteriaceae

Other Enterobacteriaceae GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known

More information

Combination vs Monotherapy for Gram Negative Septic Shock

Combination vs Monotherapy for Gram Negative Septic Shock Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham

More information

Animal Antibiotic Use and Public Health

Animal Antibiotic Use and Public Health A data table from Nov 2017 Animal Antibiotic Use and Public Health The selected studies below were excerpted from Pew s peer-reviewed 2017 article Antimicrobial Drug Use in Food-Producing Animals and Associated

More information

A Point Prevalence Survey of Antibiotic Prescriptions and Infection in Sanandaj Hospitals, Prospects for Antibiotic Stewardship

A Point Prevalence Survey of Antibiotic Prescriptions and Infection in Sanandaj Hospitals, Prospects for Antibiotic Stewardship A Point Prevalence Survey of Antibiotic Prescriptions and Infection in Sanandaj Hospitals, Prospects for Antibiotic Stewardship Jafar Soltani* Ann Versporten**, Behzad Mohsenpour*, Herman Goossen**, Soheila

More information

Le infezioni di cute e tessuti molli

Le infezioni di cute e tessuti molli Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections

More information

Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms

Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms Nimalie D. Stone, MD,MS Division of Healthcare Quality Promotion National

More information

Introduction to antimicrobial resistance

Introduction to antimicrobial resistance Introduction to antimicrobial resistance Philip Howard Consultant Antimicrobial Pharmacist HCAI and AMR Project Lead 4 th March 2015 What is antimicrobial resistance? Antibacterials either kill or stop

More information

Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days

Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of

More information

Dr.Asad A. Khan FRCPC Consultant, Division of Infectious Diseases Tawam Hospital Al Ain, UAE

Dr.Asad A. Khan FRCPC Consultant, Division of Infectious Diseases Tawam Hospital Al Ain, UAE MDR Enterobacteriaceae in community acquired infections Dr.Asad A. Khan FRCPC Consultant, Division of Infectious Diseases Tawam Hospital Al Ain, UAE Introduction Case presentation Epidemiology Objectives

More information

Antimicrobial stewardship in managing septic patients

Antimicrobial stewardship in managing septic patients Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest

More information

Source: Portland State University Population Research Center (

Source: Portland State University Population Research Center ( Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:

More information

Questions and answers about methicillin-resistant Staphylococcus aureus (MRSA)

Questions and answers about methicillin-resistant Staphylococcus aureus (MRSA) Questions and answers about methicillin-resistant Staphylococcus aureus (MRSA) Updated FAQ, 18 November 2014 Methicillin-resistant Staphylococcus aureus (MRSA) are bacteria which are resistant to certain

More information

Surgical prophylaxis for Gram +ve & Gram ve infection

Surgical prophylaxis for Gram +ve & Gram ve infection Surgical prophylaxis for Gram +ve & Gram ve infection Professor Mark Wilcox Clinical l Director of Microbiology & Pathology Leeds Teaching Hospitals & University of Leeds, UK Heath Protection Agency Surveillance

More information

MRSA in the United Kingdom status quo and future developments

MRSA in the United Kingdom status quo and future developments MRSA in the United Kingdom status quo and future developments Dietrich Mack Chair of Medical Microbiology and Infectious Diseases The School of Medicine - University of Wales Swansea P R I F Y S G O L

More information

Exploring the Role of Antibiotics on VRE Colonization and Infection

Exploring the Role of Antibiotics on VRE Colonization and Infection Exploring the Role of Antibiotics on VRE Colonization and Infection Dr. James McKinnell, Dr. Loren Miller, Dr. Arnold Bayer K30 Fellow Harbor-UCLA/University of Alabama Background Enterococcus Spp. are

More information

EFSA s activities on Antimicrobial Resistance

EFSA s activities on Antimicrobial Resistance EFSA s activities on Antimicrobial Resistance CRL-AR, Copenhagen 23 April 2009 Annual Workshop of CRL - AR 1 Efsa s Role and Activities on AMR Scientific advices Analyses of data on AR submitted by MSs

More information

Antimicrobial Resistance

Antimicrobial Resistance Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length

More information

Antimicrobial Resistance Acquisition of Foreign DNA

Antimicrobial Resistance Acquisition of Foreign DNA Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple

More information

ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES

ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES ANTIMICROBIAL STEWARDSHIP COLLABORATIVE COLORADO HOSPITAL ASSOCIATION MARCH 23, 2016 Bridget Olson, RPh Infectious Disease Pharmacist, Sharp Coronado

More information

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta

MDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental

More information

EFSA s activities on antimicrobial resistance in the food chain: risk assessment, data collection and risk communication.

EFSA s activities on antimicrobial resistance in the food chain: risk assessment, data collection and risk communication. EFSA s activities on antimicrobial resistance in the food chain: risk assessment, data collection and risk communication. Dr. Ernesto Liebana BIOHAZ Team Leader European Food Safety Authority (EFSA) EFSA

More information

Konsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program

Konsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes

More information

Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017

Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t

More information

Antibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen

Antibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen Antibiotic usage in nosocomial infections in hospitals Dr. Birgit Ross Hospital Hygiene University Hospital Essen Infection control in healthcare settings - Isolation - Hand Hygiene - Environmental Hygiene

More information

Summary of the latest data on antibiotic consumption in the European Union

Summary of the latest data on antibiotic consumption in the European Union Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite

More information

Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10

Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 BASINGSTOKE AND NORTH HAMPSHIRE NHS FOUNDATION TRUST Glycopeptide Resistant Enterococci (GRE) Policy IC/292/10 Supersedes: IC/292/07 Owner Name Dr Nicki Hutchinson Job Title Consultant Microbiologist,

More information

Informing Public Policy on Agricultural Use of Antimicrobials in the United States: Strategies Developed by an NGO

Informing Public Policy on Agricultural Use of Antimicrobials in the United States: Strategies Developed by an NGO Informing Public Policy on Agricultural Use of Antimicrobials in the United States: Strategies Developed by an NGO Stephen J. DeVincent, DVM, MA Director, Ecology Program Alliance for the Prudent Use of

More information

Origins of Resistance and Resistance Transfer: Food-Producing Animals.

Origins of Resistance and Resistance Transfer: Food-Producing Animals. Origins of Resistance and Resistance Transfer: Food-Producing Animals. Chris Teale, AHVLA. Origins of Resistance. Mutation Brachyspira hyodysenteriae and macrolide and pleuromutilin resistance. Campylobacter

More information

2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea

2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea 2016/LSIF/FOR/007 Improving Antimicrobial Use and Awareness in Korea Submitted by: Asia Pacific Foundation for Infectious Diseases Policy Forum on Strengthening Surveillance and Laboratory Capacity to

More information

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection

More information

Vaccine Evaluation Center, BC Children s Hospital Research Institute, 950 West 28 th Ave,

Vaccine Evaluation Center, BC Children s Hospital Research Institute, 950 West 28 th Ave, Manuscript Click here to view linked References Age-specific trends in antibiotic resistance in Escherichia coli infections in Oxford, United Kingdom 2013-2014 Rebecca C Robey a, Simon B Drysdale b,c,

More information

THE NETHERLANDS VETERINARY MEDICINES AUTHORITY

THE NETHERLANDS VETERINARY MEDICINES AUTHORITY THE NETHERLANDS VETERINARY MEDICINES AUTHORITY Workshop Lithuania, Oktober 2016 Reducing usage of antimicrobials in livestock: The Dutch approach Hetty van Beers-Schreurs, DVM, PhD SHORT INTRODUCTION Educated

More information

Human health impacts of antibiotic use in animal agriculture

Human health impacts of antibiotic use in animal agriculture Human health impacts of antibiotic use in animal agriculture Beliefs, opinions, and evidence Peter Davies BVSc, PhD College of Veterinary Medicine, University of Minnesota, USA Terminology Antibiotic Compound

More information

RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR

RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department

More information

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance

More information

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges

MAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control

More information